Pharma marketers have spent years talking about connecting HCP and consumer campaigns. Usually, that conversation has meant coordination: making sure the patient campaign and physician campaign tell compatible stories, align their timing, and avoid having two teams operate as though they support different brands.
A newer development goes further.
HCP intelligence is beginning to influence the construction of the consumer audience itself.
PulsePoint’s newly launched DTC Explorer offers a particularly clear example. The platform allows health marketers to build clinically informed consumer audiences using de-identified diagnosis, drug, and treatment claims, while also providing an HCP-to-DTC crosswalk that can begin with inputs such as an NPI list, prescriber specialty, or patient diagnosis profile.
That changes the conversation around how HCP intelligence informs DTC audience strategy.
This is no longer only about whether HCP and DTC teams coordinate their media plans. It is about what happens when intelligence generated on the professional side of a pharma organization starts helping determine which consumer populations are eligible for media on the other side.
Table of Contents
- From Coordinated Campaigns to Connected Audiences
- The Physician Target List Becomes a Consumer Planning Input
- Why the Architecture Matters More Than the Tool
- Audience Precision Can Change the Strategic Question
- Privacy Becomes an Audience-Design Issue
- Measurement Gets More Complicated—and More Interesting
- Pharma Teams May Need New Governance Around Audience Creation
- What Marketers Should Watch Next
- The Bigger Shift Is From Coordination to Audience Architecture
- Frequently Asked Questions
From Coordinated Campaigns to Connected Audiences
Traditional HCP and DTC planning often starts from different datasets.
The HCP team may analyze prescribing behavior, specialty, treatment patterns, diagnosis volumes, account characteristics, brand engagement, and other provider-level signals before producing a target list.
The consumer team may work from demographic, behavioral, contextual, geographic, disease-prevalence, claims-derived, or other audience signals.
Both campaigns can support the same commercial strategy while still being built through largely separate audience-planning processes.
DTC Explorer points toward another model.
PulsePoint says marketers can use its HCP2DTC crosswalk to anchor consumer audience creation to an HCP targeting strategy. The starting point can include an NPI list, prescriber specialty, or patient diagnosis profile, which is then used to model an associated consumer audience using the platform’s clinical-data foundation.
The important change is subtle.
The HCP strategy is no longer merely running alongside the patient strategy. It can become an input into it.
The Physician Target List Becomes a Consumer Planning Input
Consider what a traditional physician target list represents.
It is not simply a list of doctors.
Ideally, it encodes a series of strategic decisions: which specialties matter, which physicians see relevant patient populations, where treatment opportunities may exist, how prescribing behavior differs, which providers have demonstrated engagement, and where the brand believes intervention could matter.
Once those decisions can influence consumer audience construction, some of the intelligence embedded in that target list can effectively travel downstream.
PulsePoint has been moving in this direction for some time. Its HCP2DTC Influence capability, launched earlier in 2026, uses physician prescribing and engagement signals to help optimize DTC campaign delivery. CMI Media Group later applied that approach in an agency activation for an oncology brand.
DTC Explorer moves part of that connection further upstream, into audience planning itself.
That distinction matters.
Optimizing media toward a stronger audience after a campaign begins is different from allowing HCP-derived intelligence to help define the consumer audience before activation starts.
Why the Architecture Matters More Than the Tool
It would be easy to view DTC Explorer primarily as a workflow improvement.
There is certainly a speed story. PulsePoint says marketers can create, refine, and publish bespoke consumer audiences in hours, see aggregate audience counts while adjusting filters, and publish audiences directly into its platform. The audiences can also refresh as new claims information arrives.
But faster segment creation may be less consequential than the underlying architecture.
Historically, many pharma media plans have contained a conceptual break between professional and consumer audiences. The HCP team identifies the physicians that matter. The DTC team identifies the patients or consumers it wants to reach. Coordination happens later through messaging, sequencing, geography, measurement, or broader omnichannel planning.
Connected audience systems can move that integration much earlier in the planning process.
Instead of asking:
Who are our priority physicians?
and separately:
Who are our likely patients?
a planning team could increasingly ask:
What consumer population logically corresponds to the clinical ecosystem represented by our priority HCPs?
That is a different strategic question.
Audience Precision Can Change the Strategic Question
More precise targeting does not necessarily mean marketers should always pursue the narrowest possible audience.
The value of HCP-informed DTC targeting may instead come from making audience assumptions more explicit.
Suppose a brand identifies a particular group of specialists as strategically important because they treat a disproportionately relevant patient population.
The consumer team could potentially use that physician strategy as another signal for determining where and how patient media should be concentrated.
For another brand, broad disease education may still require substantially wider reach.
The technology does not eliminate that strategic choice. It simply makes it easier to translate the decision into audience criteria.
That can be valuable because audience definitions often contain assumptions that disappear once a segment is converted into a line item in a media plan.
Why this population? Why this geography? Why this clinical signal? Why this physician cohort?
A more connected planning approach can make those relationships—and the assumptions behind them—more visible.
It also makes documenting them more important.
Privacy Becomes an Audience-Design Issue
The closer targeting gets to clinical behavior, the more carefully marketers need to think about privacy and governance.
PulsePoint says its consumer Bespoke Audiences are built from de-identified diagnosis, drug, and treatment claims, and its broader DTC targeting approach uses modeled, de-identified clinical and digital behavioral information rather than personally identifiable information.
De-identification is an important distinction, but it should not turn privacy into a checkbox.
HHS notes that properly de-identified health information is no longer treated as protected health information under the HIPAA Privacy Rule. It also notes that de-identification reduces identification risk rather than making that risk mathematically zero.
For pharma marketers, the practical question should therefore extend beyond whether a dataset qualifies under a particular technical or legal definition.
Teams should also ask what kinds of audience combinations are appropriate, how granular segments should become, what minimum audience thresholds are required, how data flows across vendors, what information planners can actually see, and how activation partners prevent individual-level health inferences from being exposed.
The more powerful audience-building tools become, the more important those guardrails become.
Measurement Gets More Complicated—and More Interesting
Connecting HCP intelligence with DTC audience construction can also complicate attribution.
If a consumer campaign performs better after its audience has been informed by physician-level strategy, which part deserves credit?
Was performance driven by:
- stronger consumer targeting,
- better identification of relevant HCPs,
- geographic alignment between providers and patients,
- changing prescribing behavior,
- media optimization,
- message exposure on both sides,
- or the interaction among several of those factors?
This matters because pharma has traditionally measured HCP and DTC programs through partly separate frameworks.
As the audience architecture becomes more connected, measurement may need to follow.
A campaign could eventually be evaluated less as two media programs—one aimed at doctors and one aimed at consumers—and more as an interconnected market-development system.
That does not make causality easier to prove.
It makes simplistic channel attribution less satisfying.
Pharma Teams May Need New Governance Around Audience Creation
Another implication involves ownership.
Who decides how HCP intelligence should affect the consumer audience?
The HCP media team?
The DTC team?
Analytics?
Data science?
The agency?
Privacy and legal reviewers?
Commercial leadership?
When professional and consumer targeting were largely separate, those responsibilities could remain relatively clean. Connected audience systems blur the boundary.
That creates several questions worth answering before a campaign launches:
What is the strategic rationale?
Teams should be able to explain why a particular HCP signal is relevant to the consumer audience rather than merely using it because the technology permits it.
How much influence should HCP data have?
A physician strategy might be one input among many rather than the dominant determinant of consumer targeting.
What happens when the datasets disagree?
Claims patterns, digital behavior, HCP engagement, epidemiology, market research, and brand strategy may point toward different populations.
Who can change the audience?
If self-service platforms allow segments to be rebuilt in hours, governance processes designed around weekslong audience requests may need to change too.
How will changes be documented?
Dynamic audiences are useful, but teams still need a record of why targeting logic changed and what effect the change had.
Speed makes governance more important, not less.
What Marketers Should Watch Next
PulsePoint is unlikely to be the last platform to push HCP and DTC intelligence closer together.
The broader direction of healthcare advertising already favors integrated data, faster audience creation, real-time optimization, and workflows in which insight and activation happen inside the same technology environment.
PulsePoint says DTC Explorer audiences can be refined using demographics, clinical signals, prescribed drugs, insurance provider, geography, and NPI lists, with aggregate audience counts updating during the process.
It also plans to make the functionality accessible through Hatch, its agentic AI platform, allowing users to describe an audience and have the system construct and publish it.
That last development may eventually matter as much as HCP-to-DTC connectivity.
Once marketers can describe an audience in natural language and have software translate that request into clinical and media criteria, audience strategy becomes easier to execute.
But easier execution places more responsibility on the quality of the original strategic instruction.
The future advantage may therefore belong less to teams that can operate targeting technology and more to teams that know precisely what audience they are trying to create—and why.
The Bigger Shift Is From Coordination to Audience Architecture
Pharma has been told for years to tear down the wall between HCP and DTC marketing.
The more interesting development may be that the wall is no longer simply coming down at the campaign level.
It is beginning to disappear inside the audience itself.
Physician intelligence can increasingly shape consumer targeting. Clinical signals can move across planning environments. Audiences can refresh as underlying data changes. Optimization can respond to activity on both sides of the healthcare ecosystem.
That creates opportunities for better coordination and greater relevance.
It also introduces harder questions about privacy, governance, measurement, and exactly how much influence one dataset should have over another.
The next phase of HCP-to-DTC audience planning is therefore not simply about making HCP and consumer teams work together.
It is about deciding what should happen when the intelligence those teams use begins to converge.
Frequently Asked Questions
What is an HCP-to-DTC audience strategy?
An HCP-to-DTC audience approach uses intelligence from healthcare-professional planning—such as provider specialties, prescribing patterns, NPI target lists, or clinical activity—to inform some aspect of direct-to-consumer audience planning or activation. It goes beyond simply coordinating HCP and patient messaging.
What is PulsePoint DTC Explorer?
DTC Explorer is a self-service audience-building workspace announced by PulsePoint in September 2026. It lets healthcare marketers construct clinically informed consumer audiences using filters including clinical signals, medications, demographics, geography, insurance information, and NPI lists.
Does HCP-to-DTC targeting mean advertisers identify individual patients of specific doctors?
That is not how PulsePoint describes the product. Its consumer audiences are described as being modeled using de-identified clinical information, while the interface provides aggregate consumer and device counts during audience construction.
Why would pharma marketers connect HCP and DTC audience planning?
The approach can help marketers align consumer media more closely with the clinical and prescribing environment surrounding a brand. The strategic value is not simply greater targeting precision, but the ability to use a more consistent clinical framework across professional and consumer planning.
What are the risks of an HCP-to-DTC audience strategy?
Key considerations include privacy, excessive audience granularity, unclear ownership of targeting decisions, reliance on imperfect data, changing audience definitions, measurement complexity, and the possibility that technical precision could substitute for sound strategic reasoning.
Will HCP and DTC media eventually become one campaign?
Not necessarily. HCPs and consumers have different information needs, regulatory considerations, channels, creative requirements, and roles in treatment decisions. However, the data and audience systems supporting those campaigns are becoming increasingly interconnected, making it harder to treat HCP and DTC planning as entirely independent disciplines.
